TECHNOLOGY LICENSING OPPORTUNITY: SignalGen
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
TRIAD - DOE CONTRACTOR
Contract Value
Not provided
Codes & Classification
Solicitation Number
S-195368
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AN12
Additional Details
Documents1
Los Alamos National Laboratory (LANL), operating under the Department of Energy (DOE) and managed by TRIAD as a federal contractor, has issued a special notice regarding a technology licensing opportunity for SignalGen—a novel platform designed to advance protein targeting in biotechnology and pharmaceutical applications. This opportunity is not a solicitation for external development services, but rather an invitation for companies to license and commercialize the SignalGen technology.
SignalGen addresses a critical challenge in the development of medicines, vaccines, and biotechnology products: ensuring that proteins reach their intended cellular compartment or are secreted outside the cell in sufficient quantities. The platform leverages generative artificial intelligence to predict the optimal signal peptide for a specific protein, taking into account the protein’s characteristics, its intended cellular destination, and the organism of origin. This predictive capability is a significant advancement over existing software, which can only identify known signal peptides or determine if a protein contains one, but cannot recommend the best sequence for desired expression and localization.
The core of SignalGen is a protein language model trained on thousands of proteins and their associated signal peptides, encompassing both human and non-human sources. By learning the relationships between proteins, signal peptides, cellular locations, and organisms, the model delivers highly accurate predictions—demonstrated at approximately 90% accuracy across all organisms. The platform features a natural-language interface, enabling researchers to interact with the system without the need for programming or scripting. An integrated AI agent guides users through the workflow, collects necessary information, and returns the recommended signal peptide, streamlining the process and reducing technical barriers.
SignalGen is positioned at Technology Readiness Level (TRL) 3, with a U.S. patent pending (reference LA-UR-26-27860). The technology is particularly valuable for applications in therapeutic protein development, vaccine research, drug discovery, biomanufacturing, protein engineering, synthetic biology, industrial biotechnology, and molecular biology research. Its versatility and ease of use make it suitable for both established and start-up companies seeking to enhance their product pipelines or research capabilities.
LANL’s technology licensing program offers both exclusive and non-exclusive agreements for patented and patent-pending inventions, as well as copyrighted software. Interested parties are encouraged to contact the LANL Tech Partnerships team for specific discussions regarding licensing arrangements. The primary and secondary contacts for this opportunity are Satya Srinivasan and Lindsay Augustyn, both reachable at [email protected].
The place of performance is Los Alamos, New Mexico, and the opportunity is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology) and Product Service Code AN12. There are no set-aside requirements for this opportunity, making it accessible to a broad range of potential licensees.
For further information, including access to the technology search portal and details on partnering with LANL, interested parties can visit:
- https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
- m.lanl.gov/tech-search
The notice remains active, with a response deadline of March 22, 2027. Contractors and companies evaluating this opportunity should consider their capabilities in biotechnology, protein engineering, and commercialization of AI-driven research tools. SignalGen represents a unique chance to license a cutting-edge platform with demonstrated accuracy and broad applicability, backed by the resources and expertise of Los Alamos National Laboratory.
For official notice details and attachments, refer to the SAM.gov listing: https://sam.gov/opp/8cdf1c48ac25413ebdb2ec1fbecfd1de/view